Published by Frank Prenesti on 2nd December 2022
(Sharecast News) - GSK said the European Medicines Agency had validated its marketing authorisation application for momelotinib, a potential new oral treatment for the blood cancer myelofibrosis after meeting key endpoints in a Phase 3 trial.
URL: http://www.digitallook.com/dl/news/story/33150686/...